For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Thymalin is a polypeptide complex extracted from the thymus glands of young calves, developed by Professors Morozov and Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology beginning in the 1970s. Unlike the synthetic single-sequence Khavinson bioregulators (Epithalon, Pinealon, Vesugen, Pancragen), Thymalin is a multi-component preparation containing short peptides including the dipeptides EW (Glu-Trp, also known as Thymogen) and KE (Lys-Glu, also known as Vilon). The most significant human clinical finding is the indexed Khavinson and Morozov (2002, 2003) long-term observational study in 266 elderly persons (over 60 years), followed 6 to 8 years, which reported a 2.0 to 2.1-fold mortality decrease in Thymalin-treated patients and a 4.1-fold decrease in the group receiving Thymalin combined with Epithalamin annually over 6 years. Thymalin is also the only Khavinson bioregulator with approved Russian pharmaceutical status, with a COVID-19 PMC study in n=36 elderly patients providing the most recent indexed human data.
The complete Thymalin profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use